#1 Clinical Trials Search in Europe

Study of MK-7684A, Etoposide, and Platinum Drugs for Patients with Extensive-Stage Small Cell Lung Cancer

3 1 1

What is this study about?

This clinical trial is focused on studying treatments for extensive-stage small-cell lung cancer (ES-SCLC), a type of lung cancer that has spread widely throughout the body. The study is comparing two different treatment combinations to see which one is more effective in helping patients live longer. One treatment involves a combination of a medication called MK-7684A with chemotherapy drugs etoposide and platinum, followed by continued treatment with MK-7684A. The other treatment involves a medication called atezolizumab combined with the same chemotherapy drugs, followed by continued treatment with atezolizumab.

The purpose of the study is to compare the overall survival of patients receiving these treatments. Participants will receive their assigned treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over several months, with regular visits to monitor the participants’ health and response to the treatment. The study will also look at other factors, such as how long the cancer stays under control and the quality of life of the participants during the treatment.

Throughout the study, some participants will receive a saline placebo as part of the treatment process. This is a standard practice in clinical trials to help researchers understand the effects of the actual medications being tested. The trial aims to provide valuable information that could lead to better treatment options for people with extensive-stage small-cell lung cancer in the future.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes reviewing medical history and current health status.

A diagnosis of extensive-stage small-cell lung cancer is required, and the condition must be at a specific stage as defined by medical guidelines.

2 treatment group assignment

Participants are randomly assigned to one of two treatment groups. This process is double-blind, meaning neither the participant nor the researchers know which group the participant is in.

One group receives MK-7684A in combination with etoposide and platinum followed by MK-7684A. The other group receives atezolizumab in combination with etoposide and platinum followed by atezolizumab.

3 treatment administration

The medications are administered through an intravenous infusion, which means they are given directly into a vein.

The specific dosage, frequency, and duration of administration are determined by the study protocol and will be explained by the healthcare team.

4 regular monitoring

Participants undergo regular monitoring to assess the effectiveness of the treatment and to check for any side effects.

This includes physical examinations, imaging tests, and laboratory tests as needed.

5 quality of life assessments

Participants complete questionnaires to evaluate their quality of life during the study. These assessments help understand the impact of the treatment on daily living.

The questionnaires cover various aspects such as physical functioning, pain, and overall health status.

6 end of treatment

At the end of the treatment period, a final assessment is conducted to evaluate the overall response to the therapy.

Participants may be asked to continue follow-up visits to monitor long-term effects and overall survival.

Who Can Join the Study?

  • The patient has a confirmed diagnosis of extensive-stage small-cell lung cancer (ES-SCLC), which means the cancer has spread widely in the body.
  • The patient has ES-SCLC that is classified as Stage IV or has large tumors in the lungs that cannot be treated with radiation.
  • Males must agree to use contraception, not donate sperm, and avoid sexual intercourse with women.
  • Females must not be pregnant or breastfeeding. If they can have children, they must use a highly effective birth control method or avoid sexual intercourse with men.
  • The patient has a disease that can be measured according to specific medical guidelines called RECIST 1.1.
  • The patient is expected to live for more than 3 months.

Who Cannot Join the Study?

  • Patients with any other type of cancer besides extensive-stage small-cell lung cancer cannot participate.
  • Patients who have had a different cancer treatment recently may not be eligible.
  • Patients with serious heart problems or uncontrolled high blood pressure cannot participate.
  • Patients with active infections, including HIV or hepatitis, are not eligible.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients with a history of severe allergic reactions to similar drugs cannot participate.
  • Patients with certain autoimmune diseases, where the immune system attacks the body, may not be eligible.
  • Patients who have had a major surgery recently may not be eligible.
  • Patients who are currently participating in another clinical trial cannot participate.
  • Patients with a history of drug or alcohol abuse may not be eligible.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Medical University Of Graz Graz Austria
Medeuropa S.R.L. Bucharest Romania

Other Sites

Site Name City Country Status
Turku University Hospital Turku Finland
Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E. Porto Portugal
Wiener Gesundheitsverbund Vienna Austria
Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawła II W Siedlcach Sp. z o.o. Siedlce Poland
LungenClinic Grosshansdorf GmbH Grosshansdorf Germany
Hcpmtzhj Vyhg dgsefuyd Barcelona Spain
Befogpga Hvxxspgb Dublin Ireland
Ajipkuynjs Pxdbtujc Hbqhhkct Dj Mcycccowh Marseille France
Csqgfv Hypkratutck Uleurljmnhplx De Twsluaws Toulouse France
Numwofef Itrolnei Ogcgaaqon Iix Mqkcc Sspaccclajoapiopqwfwefbbriqi Ickqzhmb Bwdulwbs Warsaw Poland
Ebjshct Uednajusyjhv Mmkfauz Cfvjklq Rxxrgutgz (wjwdscs Mop Rotterdam The Netherlands
Kjlxua Uxhocgvqvwdbagaugpthu Gggd Linz Austria
Anpezxb Ohbrbdizlzt Ugqnwbzgqqowj Ftignsar Id Dx Naxxpj Naples Italy
Acxpsr Mnwfmur Cjwawo Salx Thessaloniki Greece
Umdamcjqsa Hgtjpfso Mnbbjuogon Maastricht The Netherlands
Toqoqkdymfte Hrnrclufdn gyuym Heidelberg Germany
Iszyvy Iwfaxfga Febwihfsdmujy Opyjlpndalm Rome Italy
Obaufquftareji Lxsu Ghqc Linz Austria
Kwcwgrzjyfi Nycm Kgzkuw Fuawlwvqszs Vienna Austria
Oefn Uibuhvufdr Hvjgqvav Oulu Finland
Fogvjoctot Iyivyfgwhc Ilwawwjh Ndfagunxguh Booqe Milan Italy
Cztqkjj De Obuuzyhcq Sa Ntzyszdm Snyzdn Craiova Romania
Bkciivbpshf Vdxqcgfvp Oomgykeskzsv Kecskemet Hungary
Sdnfvq Vsrgsvaxg Kinyhd Mby Oyatfu Kygijs Kaposvar Hungary
Mkv Piuuqbw Sxi z opth Poznan Poland
Vcbgwcikp ircfcvfj Vejhnhbw urhfosgvxwtj ldkccnahl Stztpnbd klisbyg flhfuaab Nusxxiygvfcc vypae ctjuybx Vilnius Lithuania
Piubccrcrqj Lltuacke &wcivrtlfqmcyqmdhjtq Ribzr Koyxjdcrydz Konin Poland
Mdmphkynpcla Hequvaqy Athens Greece
Cclcwr Htlhqlimwqm Eb Ueueexqnjraea Dg Lkoigqy Limoges France
Cgkzpdfbewdf Crkmqotu Cstmfs Lisbon Portugal
Mdkgmrl Ciibhyp Lzzejvvxyd Bssd Leeuwarden The Netherlands
Tqehwhilbjaioobfp Ttitqrwkzogku Torokbalint Hungary
Creren Hmiqijuuxj Uffjsagsumgot Dc Ppska Ehasxs Porto Portugal
Sxmnrxy Svpouifbfyjwckt W Phoqatnvu Sts z orwq Prabuty Poland
Ilvkn Kyxnbhgfo Svzqpgypt Zwolle The Netherlands
Swm Wkazgklqduzif Gvly Gbsz Gera Germany
Jpcvzi Bovwv Zrnhjufhdp Sszgsdfoa S-Hertogenbosch The Netherlands
Lzydonpz scedxwfgz mcxwqv uvebzlrjaont lkrrplzt Kbwnt keqqafgv Kaunas Lithuania
Hbgmjkct Ciy Dcnseotgkdf Schn Lisbon Portugal
Vqaye Cxtcvgs Hefpligc Vaasa Finland
Hnrcy Dcweia Hpwrpzpl Cvtjnj Athens Greece
Crwgpma Pqohiwgwxlnj I Tbolsetbkzvkwmr W Bpnlsxx Wilkowice Poland
Tiushnlo Gxgeybp Hycnpgtg Od Afafrq I Svwosof Athens Greece
Wjjveklwxq Smanooz Isu Sywlffd Pbk W Pujhvlwbw Przemysl Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Austria Austria
Not recruiting
31.03.2022
Finland Finland
Not recruiting
31.03.2022
France France
Not recruiting
31.03.2022
Germany Germany
Not recruiting
31.03.2022
Greece Greece
Not recruiting
31.03.2022
Hungary Hungary
Not recruiting
31.03.2022
Ireland Ireland
Not recruiting
31.03.2022
Italy Italy
Not recruiting
31.03.2022
Lithuania Lithuania
Not recruiting
31.03.2022
Poland Poland
Not recruiting
31.03.2022
Portugal Portugal
Not recruiting
31.03.2022
Romania Romania
Not recruiting
31.03.2022
Spain Spain
Not recruiting
31.03.2022
The Netherlands The Netherlands
Not recruiting
31.03.2022

Trial locations

Investigated Drugs:

MK-7684A is an experimental medication being tested in this clinical trial. It is being studied to see if it can help treat extensive-stage small cell lung cancer. This medication is used in combination with other cancer treatments to see if it can improve the overall survival of patients. It is given to patients after they receive a combination of other cancer drugs, and researchers are trying to find out if it works better than another medication called atezolizumab.

Etoposide is a medication used in this trial as part of a combination treatment for extensive-stage small cell lung cancer. It works by interfering with the growth of cancer cells, which are eventually destroyed. Etoposide is often used with other cancer drugs to enhance its effectiveness in treating cancer.

Platinum refers to a group of chemotherapy drugs that contain the metal platinum. In this trial, a platinum-based drug is used alongside etoposide and other medications to treat extensive-stage small cell lung cancer. These drugs work by damaging the DNA of cancer cells, which helps to stop their growth and spread.

Atezolizumab is another medication being tested in this trial. It is an immunotherapy drug that helps the body’s immune system fight cancer. Atezolizumab is used in combination with etoposide and a platinum-based drug to treat extensive-stage small cell lung cancer. The trial aims to compare the effectiveness of atezolizumab with the experimental drug MK-7684A in improving patient survival.

Extensive-stage small-cell lung cancer – This is a type of lung cancer characterized by the rapid growth and spread of small cancerous cells in the lungs. It is called “extensive-stage” when the cancer has spread beyond the lungs to other parts of the body. The disease progresses quickly, often involving the lymph nodes and other organs. Symptoms may include coughing, chest pain, shortness of breath, and fatigue. As the cancer advances, it can lead to more severe respiratory issues and systemic symptoms. The progression is typically aggressive, requiring prompt medical attention.

Trial ID:
2023-503517-30-00
Protocol code:
MK-7684A-008
NCT ID:
NCT05224141
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium Czechia Denmark France Germany +5

  • BMS-986525 Alone and with Nivolumab in Patients with Relapsed or Refractory Small Cell Lung Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy Romania Spain